The short answer
"NAD+" and "peptide therapy" are broad marketing categories. They do not give you enough information to make a medical decision. You need the exact active ingredient, route, intended use, FDA-approval status, evidence for that use, pharmacy information, and a clinician who can explain why it is being considered for you.
This scrutiny is especially important for compounded sterile injectables. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing.
1. What exactly is the product?
Ask for the full active ingredient, concentration, route, dosage form, and the name of the dispensing pharmacy. "Peptide," "longevity," "recovery," or "NAD support" is not a product identity.
Also ask whether the prescription is a single ingredient or a combination. Do not assume two products with similar marketing names have the same composition, quality controls, or evidence.
2. Is it FDA-approved for this use?
An FDA-approved drug has been reviewed for a specific use, formulation, and labeling. A compounded drug has not gone through that approval process. A service should state the difference directly instead of using phrases that imply FDA review of the finished compounded product.
Ask whether an FDA-approved option can meet the same medical need and why a compounded product is being considered. The answer should be specific to your situation.
3. What human evidence supports the claimed benefit?
Cell studies, animal research, biological plausibility, and a small uncontrolled human study are not equivalent to a well-designed clinical trial showing a meaningful patient outcome. Ask what population was studied, what outcome changed, how large the effect was, and what remains uncertain.
Be cautious when a broad promise such as energy, anti-aging, recovery, immunity, or body composition is attached to one compound without an evidence boundary.
4. Who compounded and dispensed it?
Get the pharmacy's legal name, address, and state-license information. FDA directs consumers to state boards of pharmacy when checking online pharmacy licensure. Ask whether the pharmacy is a traditional state-licensed compounder or an FDA-registered outsourcing facility and what that distinction means.
Registration or inspection language should not be turned into a claim that a compounded prescription is FDA-approved.
5. How is sterility and ingredient suitability addressed?
Sterile injectables add contamination and endotoxin risks. FDA has specifically reported adverse events after NAD+ injectable products and warned compounders not to use food-grade ingredients in sterile drugs without appropriate processing.
A patient cannot personally audit a sterile facility, but a provider should be able to identify the pharmacy, explain its selection process, and give clear instructions for storage, inspection, handling, and reporting a suspected quality problem.
6. What does the clinician monitor?
Ask what baseline history, examination, or testing is needed; which effects or side effects will be tracked; how response will be judged; and when the plan will be reconsidered. A recurring shipment is not the same as clinical monitoring.
Tell the clinician about all medicines, supplements, allergies, prior reactions, pregnancy potential, and health conditions. Do not combine wellness injections or change a prescribed plan on your own.
7. What happens if the answer is no?
A legitimate evaluation can end without a prescription. Ask what alternatives exist, whether an in-person assessment is more appropriate, what charges remain if treatment is not prescribed, and how cancellation works.
If the sales experience makes one product feel inevitable before a clinician reviews you, the commercial promise is outrunning the medical decision.
Keep these points
- Demand the exact product identity, regulatory status, evidence, and pharmacy. A wellness category name is not enough.
- Compounded sterile injectables carry quality questions that marketing language cannot answer.
- A clinician-led process must allow for uncertainty, alternatives, monitoring, and a decision not to prescribe.
Sources
- U.S. Food and Drug Administration: Reminder to compounders about ingredients suitable for sterile compounding. Accessed September 9, 2026.
- U.S. Food and Drug Administration: Compounding and the FDA, questions and answers. Accessed September 9, 2026.
- U.S. Food and Drug Administration: Bulk drug substances that may present significant safety risks. Accessed September 9, 2026.
This guide provides general information. It does not replace care from a licensed clinician or the instructions supplied with a prescription.